A rational targeted therapy for platinum-resistant small-cell lung cancer

Benjamin J Drapkin; John D Minna

doi:10.1016/j.ccell.2021.03.003

A rational targeted therapy for platinum-resistant small-cell lung cancer

Cancer Cell. 2021 Apr 12;39(4):453-456. doi: 10.1016/j.ccell.2021.03.003.

Authors

Benjamin J Drapkin¹, John D Minna²

Affiliations

¹ Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas TX; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas TX. Electronic address: benjamin.drapkin@utsouthwestern.edu.
² Hamon Center for Therapeutic Oncology Research, Simmons Comprehensive Cancer Center, University of Texas Southwestern Medical Center, Dallas TX; Department of Internal Medicine, University of Texas Southwestern Medical Center, Dallas TX; Department of Pharmacology, University of Texas Southwestern Medical Center, Dallas TX.

PMID: 33848475
DOI: 10.1016/j.ccell.2021.03.003

Abstract

Small-cell lung cancer (SCLC) is initially sensitive to platinum doublet chemotherapy, providing dramatic clinical benefit. Unfortunately, most SCLCs relapse and become resistant to further therapy. In this issue of Cancer Cell, Thomas et al. show that some platinum-resistant SCLCs benefit from combination therapy with topotecan plus the ATR (ataxia telangiectasia-mutated and rad3-related) inhibitor berzosertib.

Publication types

Research Support, N.I.H., Extramural
Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols
Humans
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Platinum* / therapeutic use
Topotecan / therapeutic use

Substances

Platinum
Topotecan

Abstract

Publication types

MeSH terms

Substances

Grants and funding